Elucidating the therapeutic potential of targeting aryl hydrocarbon receptors in macrophages in pancreatic ductal adenocarcinoma to improve immunotherapy

阐明针对胰腺导管腺癌巨噬细胞中芳基烃受体改善免疫治疗的治疗潜力

• 批准号: 428966
• 负责人: Liu Zhe Qi
• 金额: $ 1.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-12-01 至 2020-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=428966&lang=en
• 关键词: Cancer Immunotherapy; Cyototoxic T Lymphocytes; Immunosuppression; Immunotolerance; Macrophages; Pancreatic Ductal Adenocarcinoma; Therapeutic Validation; Tumour Microenvironment

"Pancreatic ductal adenocarcinoma (PDAC) is a malignant cancer of the pancreas and has the lowest 5-year patient survival rate of all major cancer types. Cancer immunotherapy is an increasingly popular and promising approach to treating cancer patients. I

“胰腺导管腺癌 (PDAC) 是一种胰腺恶性肿瘤，在所有主要癌症类型中患者 5 年生存率最低。癌症免疫疗法是一种日益流行且有前景的癌症患者治疗方法。